Patents by Inventor Amy Heimberger
Amy Heimberger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11065285Abstract: The invention disclosed herein describes biomarkers useful for prognosis, selection and monitoring of oncolytic virus therapy for patients with various types of cancer. In particular, the present invention provides identification of proteins whose expression patterns are strongly predictive of the outcome of oncolytic virus therapy in a patient with cancer. The present invention provides a method for identifying and selecting cancer patients who are likely to be non-responsive to onocolytic virus therapy. These patients can be co-administered an agent that stimulates a cell-mediated immune response in the patient with the oncolytic virus or can be administered a therapy other than oncolytic virus therapy.Type: GrantFiled: June 30, 2020Date of Patent: July 20, 2021Assignees: DNATRIX, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Frank Tufaro, Charles Conrad, Juan Fueyo-Margareto, Frederick Lang, Jr., Candelaria Gomez-Manzano, W.K. Alfred Yung, Amy Heimberger
-
Publication number: 20200330533Abstract: The invention disclosed herein describes biomarkers useful for prognosis, selection and monitoring of oncolytic virus therapy for patients with various types of cancer. In particular, the present invention provides identification of proteins whose expression patterns are strongly predictive of the outcome of oncolytic virus therapy in a patient with cancer. The present invention provides a method for identifying and selecting cancer patients who are likely to be non-responsive to onocolytic virus therapy. These patients can be co-administered an agent that stimulates a cell-mediated immune response in the patient with the oncolytic virus or can be administered a therapy other than oncolytic virus therapy.Type: ApplicationFiled: June 30, 2020Publication date: October 22, 2020Inventors: Frank TUFARO, Charles CONRAD, Juan FUEYO-MARGARETO, Frederick LANG, JR., Candelaria GOMEZ-MANZANO, W.K. Alfred YUNG, Amy HEIMBERGER
-
Publication number: 20190269744Abstract: The invention disclosed herein describes biomarkers useful for prognosis, selection and monitoring of oncolytic virus therapy for patients with various types of cancer. In particular, the present invention provides identification of proteins whose expression patterns are strongly predictive of the outcome of oncolytic virus therapy in a patient with cancer. The present invention provides a method for identifying and selecting cancer patients who are likely to be non-responsive to onocolytic virus therapy. These patients can be co-administered an agent that stimulates a cell-mediated immune response in the patient with the oncolytic virus or can be administered a therapy other than oncolytic virus therapy.Type: ApplicationFiled: March 5, 2019Publication date: September 5, 2019Inventors: Frank TUFARO, Charles CONRAD, Juan FUEYO-MARGARETO, Frederick LANG, JR., Candelaria GOMEZ-MANZANO, W.K. Alfred YUNG, Amy HEIMBERGER
-
Patent number: 10238698Abstract: The invention disclosed herein describes biomarkers useful for prognosis, selection and monitoring of oncolytic virus therapy for patients with various types of cancer. In particular, the present invention provides identification of proteins whose expression patterns are strongly predictive of the outcome of oncolytic virus therapy in a patient with cancer. The present invention provides a method for identifying and selecting cancer patients who are likely to be non-responsive to onocolytic virus therapy. These patients can be co-administered an agent that stimulates a cell-mediated immune response in the patient with the oncolytic virus or can be administered a therapy other than oncolytic virus therapy.Type: GrantFiled: January 25, 2013Date of Patent: March 26, 2019Assignees: DNATRIX, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Frank Tufaro, Charles Conrad, Juan Fueyo-Margareto, Frederick Lang, Jr., Candelaria Gomez-Manzano, W. K. Alfred Yung, Amy Heimberger
-
Publication number: 20180215789Abstract: The concurrent administration of chemotherapy and immunotherapy has been considered a contraindication because of the concern that the induced lymphopenia would ablate therapeutic efficacy of immunotherapy. Temozolomide has been shown to be an effective chemotherapeutic for patients with malignant gliomas and to deprive patients with glioblastoma (GBM) patients of this agent in order to treat with immunotherapy is controversial. Despite conventional dogma, we demonstrate that both chemotherapy and immunotherapy can be delivered concurrently without negating the effects of immunotherapy. In fact, the temozolomide induced lymphopenia may actually be synergistic with a peptide vaccine.Type: ApplicationFiled: March 28, 2018Publication date: August 2, 2018Applicants: Duke University, Board of Regents, The University of Texas SystemInventors: John H. Sampson, Darell D. Bigner, Duane A. Mitchell, Amy Heimberger
-
Publication number: 20170312304Abstract: In some aspects, miRNA for the treatment of cancer are provided. In some embodiments, a miRNA (e.g., miR-124, miR-142, and/or miR-138) may be used to promote or enhance immune destruction of a cancer, or reduce the immune suppression of the cancer, in a subject. In other aspects, the miRNA may be used in, or in combination with, an adoptive immunotherapy.Type: ApplicationFiled: May 9, 2017Publication date: November 2, 2017Applicant: Board of Regents, The University of Texas SystemInventors: Amy HEIMBERGER, Jun WEI
-
Patent number: 9675633Abstract: In some aspects, miRNA for the treatment of cancer are provided. In some embodiments, a miRNA (e.g., miR-124, miR-142, and/or miR-138) may be used to promote or enhance immune destruction of a cancer, or reduce the immune suppression of the cancer, in a subject. In other aspects, the miRNA may be used in, or in combination with, an adoptive immunotherapy.Type: GrantFiled: March 14, 2014Date of Patent: June 13, 2017Assignee: Board of Regents, The University of Texas SystemInventors: Amy Heimberger, Jun Wei
-
Patent number: 9399662Abstract: The concurrent administration of chemotherapy and immunotherapy has been considered a contraindication because of the concern that the induced lymphopenia would ablate therapeutic efficacy of immunotherapy. Temozolomide has been shown to be an effective chemotherapeutic for patients with malignant gliomas and to deprive patients with glioblastoma (GBM) patients of this agent in order to treat with immunotherapy is controversial. Despite conventional dogma, we demonstrate that both chemotherapy and immunotherapy can be delivered concurrently without negating the effects of immunotherapy, hi fact, the temozolomide induced lymphopenia may actually be synergistic with a peptide vaccine.Type: GrantFiled: November 2, 2006Date of Patent: July 26, 2016Assignees: Duke University, Board of Regents, The University of Texas SystemInventors: John H. Sampson, Darell D. Bigner, Duane Mitchell, Amy Heimberger
-
Publication number: 20160022728Abstract: In some aspects, miRNA for the treatment of cancer are provided. In some embodiments, a miRNA (e.g., miR-124, miR-142, and/or miR-138) may be used to promote or enhance immune destruction of a cancer, or reduce the immune suppression of the cancer, in a subject. In other aspects, the miRNA may be used in, or in combination with, an adoptive immunotherapy.Type: ApplicationFiled: March 14, 2014Publication date: January 28, 2016Applicant: Board of Regents, The University of Texas SystemInventors: Amy HEIMBERGER, Jun WEI
-
Publication number: 20150118181Abstract: The concurrent administration of chemotherapy and immunotherapy has been considered a contraindication because of the concern that the induced lymphopenia would ablate therapeutic efficacy of immunotherapy. Temozolomide has been shown to be an effective chemotherapeutic for patients with malignant gliomas and to deprive patients with glioblastoma (GBM) patients of this agent in order to treat with immunotherapy is controversial. Despite conventional dogma, we demonstrate that both chemotherapy and immunotherapy can be delivered concurrently without negating the effects of immunotherapy. In fact, the temozolomide induced lymphopenia may actually be synergistic with a peptide vaccine.Type: ApplicationFiled: December 9, 2014Publication date: April 30, 2015Applicants: Board of Regents, The University of Texas System, DUKE UNIVERSITYInventors: John H. Sampson, Darell Bigner, Duane A. Mitchell, Amy Heimberger
-
Publication number: 20140377221Abstract: The invention disclosed herein describes biomarkers useful for prognosis, selection and monitoring of oncolytic virus therapy for patients with various types of cancer. In particular, the present invention provides identification of proteins whose expression patterns are strongly predictive of the outcome of oncolytic virus therapy in a patient with cancer. The present invention provides a method for identifying and selecting cancer patients who are likely to be non-responsive to onocolytic virus therapy. These patients can be co-administered an agent that stimulates a cell-mediated immune response in the patient with the oncolytic virus or can be administered a therapy other than oncolytic virus therapy.Type: ApplicationFiled: January 25, 2013Publication date: December 25, 2014Applicants: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, DNATRIX INC.Inventors: Frank Tufaro, Charles Conrad, Juan Fueyo-Margareto, Frederick Lang, Candelaria Gomez-Manzano, W.K. Alfred Yung, Amy Heimberger
-
Publication number: 20130129675Abstract: Methods of modulating the INF-induced STAT3 activation in a patient in need-thereof are provided for the treatment of disease. The methods comprise the step of administrating to a patient the combination of a therapeutically effective amount of interferon including INF-? and/or INF-? in combination with a STAT3 inhibitor.Type: ApplicationFiled: December 4, 2010Publication date: May 23, 2013Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Waldemar Priebe, Amy Heimberger, Izabela Fokt, Jayakmuar Arumugam, Ling-Yuan Kong, Timothy Madden, Charles Conrad
-
Publication number: 20090220551Abstract: The concurrent administration of chemotherapy and immunotherapy has been considered a contraindication because of the concern that the induced lymphopenia would ablate therapeutic efficacy of immunotherapy. Temozolomide has been shown to be an effective chemotherapeutic for patients with malignant gliomas and to deprive patients with glioblastoma (GBM) patients of this agent in order to treat with immunotherapy is controversial. Despite conventional dogma, we demonstrate that both chemotherapy and immunotherapy can be delivered concurrently without negating the effects of immunotherapy, in fact, the temozolomide induced lymphopenia may actually be synergistic with a peptide vaccine.Type: ApplicationFiled: November 2, 2006Publication date: September 3, 2009Applicants: Duke University, Univeristy of Texas M.D. Anderson Cancer CenterInventors: John H. Sampson, Darell D. Bigner, Mitchell Duane, Amy Heimberger